| Authors: |
López Mármol Á; Synthetic Molecules CMC R&D, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein 67061, Germany., Barker R; Global Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK102NA, U.K., Koziolek M; Synthetic Molecules CMC R&D, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein 67061, Germany., Schwabe R; Material and Analytical Sciences, Research and Development, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877, United States., Hens B; Pfizer, Drug Product Design, Pfizer Belgium, Hermeslaan 11, Zaventem 1932, Belgium., Sarcevica I; Biowaived, GS.021 Discovery Park House, Ramsgate Road, Discovery Park, Sandwich CT139NJ, U.K., Butler JM; GlaxoSmithKline R&D, Biopharmaceutics, Drug Product Development, David Jack Research Centre Harris's Lane, Ware, Hertfordshire SG12 0GX, U.K., McAllister M; Biowaived, GS.021 Discovery Park House, Ramsgate Road, Discovery Park, Sandwich CT139NJ, U.K., Taylor E; GlaxoSmithKline R&D, Biopharmaceutics, Drug Product Development, David Jack Research Centre Harris's Lane, Ware, Hertfordshire SG12 0GX, U.K., Chiang PC; Small Molecule Pharmaceutical Sciences, Genentech, 1 DNA Way, South San Francisco, California 94080, United States., Stainforth N; CMC Regulatory, AstraZeneca, Macclesfield SK102NA, U.K., Jones E; Strathclyde Institute of Pharmacy and Biomedical Sciences, 161 Cathedral Street, Glasgow G4 0RE, U.K., Batchelor H; Strathclyde Institute of Pharmacy and Biomedical Sciences, 161 Cathedral Street, Glasgow G4 0RE, U.K. |
